All PlansCoverageMedium impact
08.01.34d, Exon Skipping Drugs for Duchenne Muscular Dystrophy (DMD) (Eteplirsen (Exondys 51), Golodirsen (Vyondys 53), Viltolarsen (Viltepso), Casimersen (Amondys 45))
Independence Blue Cross·Neurology, Pediatrics, Pharmacy·Pharmacy
Effective date
Oct 29, 2025
We identified it
Jun 19, 2026
Summary
This is a reissue of the existing policy 08.01.34d covering exon-skipping drugs for Duchenne Muscular Dystrophy (DMD), effective October 29, 2025. The policy addresses coverage and billing for four specific medications: Eteplirsen (Exondys 51), Golodirsen (Vyondys 53), Viltolarsen (Viltepso), and Casimersen (Amondys 45). Without access to the full policy text, specific coverage changes cannot be determined, but billing teams should review the reissued policy for any updates to prior authorization requirements, coverage criteria, or billing guidelines.
Action Required
By October 29, 2025: Billing and clinical teams must review the full reissued policy 08.01.34d to identify any changes from the previous version. Update billing system documentation, prior authorization workflows, and clinical staff communication regarding coverage criteria for Eteplirsen (Exondys 51), Golodirsen (Vyondys 53), Viltolarsen (Viltepso), and Casimersen (Amondys 45). Verify whether any changes affect prior authorization requirements, patient eligibility criteria, or documentation needs. Failure to implement policy changes may result in claim denials or delays for DMD patients requiring these specialized medications.